Related Experiment Video
Updated: Nov 3, 2025

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
Published on: April 17, 2013
BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells
Elisa Bonaldi1, Chiara Gargiuli2, Loris De Cecco2
1Molecular Mechanisms Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
Abstract:
BRAF is the most frequent oncogenic mutation identified in papillary thyroid cancer (PTC). In PTC patients who do not respond to standard treatment, BRAF inhibitors are currently tested as alternative strategies. However, as observed for other targeted therapies, patients eventually develop drug resistance. The mechanisms of BRAF inhibitors response are still poorly understood in a thyroid cancer (TC) context. In this study, we investigated in BRAF mutated TC cell lines the effects of Vemurafenib and Dabrafenib, two BRAF inhibitors currently used in a clinical setting. We assessed cell proliferation, and the expression and activity of the thyroid function related transporter NIS following the treatment with BRAF inhibitors. In addition, we investigated the global gene expression by microarray, the relevant modulated biological processes by gene set enrichment analysis (GSEA), and TC specific gene signatures related to MAPK pathway activation, thyroid differentiation, and transcriptional profile associated with BRAF or RAS mutation. We found that both inhibitors induce antiproliferative and redifferentiative effects on TC cells, as well as a rewiring of the MAPK pathway related to RAS signaling. Our results suggest a possible mechanism of drug response to the BRAF inhibitors Vemurafenib or Dabrafenib, supporting very recent findings in TC patients treated with targeted therapies.
Insights
BRAF inhibitors like Vemurafenib and Dabrafenib show antiproliferative and redifferentiative effects in papillary thyroid cancer (PTC) cell lines. These BRAF inhibitors also rewire the MAPK pathway, offering insights into targeted therapy response mechanisms.
Area of Science:
- Oncology
- Molecular Biology
- Endocrinology
Background:
- BRAF mutations are common in papillary thyroid cancer (PTC).
- BRAF inhibitors are used for treatment-resistant PTC, but resistance mechanisms are unclear.
- Understanding BRAF inhibitor response is crucial for optimizing targeted therapies in thyroid cancer.
Purpose of the Study:
- To investigate the effects of Vemurafenib and Dabrafenib on BRAF-mutated thyroid cancer (TC) cell lines.
- To explore the mechanisms underlying BRAF inhibitor response in TC.
- To analyze gene expression and pathway modulation following targeted therapy.
Main Methods:
- Treatment of BRAF-mutated TC cell lines with Vemurafenib and Dabrafenib.
- Assessment of cell proliferation and NIS transporter activity.
- Global gene expression analysis using microarrays and gene set enrichment analysis (GSEA).
Main Results:
- Both BRAF inhibitors demonstrated antiproliferative and redifferentiative effects on TC cells.
- Treatment led to a rewiring of the MAPK pathway, with increased RAS signaling.
- Gene expression analysis revealed modulation of pathways related to MAPK activation and thyroid differentiation.
Conclusions:
- Vemurafenib and Dabrafenib induce significant anti-cancer effects in BRAF-mutated TC.
- A MAPK pathway rewiring towards RAS signaling is a key response mechanism.
- Findings provide insights into targeted therapy response in thyroid cancer, aligning with recent clinical observations.
Related Concept Videos
The Ras Gene
Ras is a...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
MAPK Signaling Cascades
PI3K/mTOR/AKT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

